Please Wait.....
Report
Dyslipidemia - Epidemiology Forecast to 2032
Market Report (24 hrs) I 2022-05-01 I 101 Pages I DelveInsight
DelveInsights Dyslipidemia Epidemiology Forecast 2032 report delivers an in-depth understanding of the historical and forecasted epidemiology of Dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
Dyslipidemia: Disease Understanding
Dyslipidemia Overview
Dyslipidemias (defined as raised plasma concentrations of total cholesterol, LDL cholesterol or triglycerides, or a low plasma concentration of HDL cholesterol or a combination of these features) are major risk factors for ischemic heart disease (IHD).
This condition can result from diet, tobacco exposure, or genetics and can lead to cardiovascular disease with severe complications. These lipids are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation. Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of these factors, either from organic or nonorganic causes, can lead to dyslipidemia.
It is divided into two types, primary and secondary. Primary dyslipidemia comes through genes, and secondary dyslipidemia is acquired, which is developed from other issues like obesity or diabetes. Hyperlipidemia is often confused with dyslipidemia. Hyperlipidemia is caused when LDL levels are high, but dyslipidemia is caused by blood fats being either low or high. Hyperlipidemia is a major cause of atherosclerosis, and it includes conditions like ischemic cardiovascular issues, coronary heart disease, and peripheral vascular disease.
High cholesterol has no symptoms, and a blood test is the only way to detect it. History is essential in identifying high-risk individuals. Most importantly, social history would include tobacco use or specific details about diet. Past medical history is vital in identifying patients who need primary prevention versus secondary prevention if statin therapy requires initiation. Lastly, family history is vital to identify.
Dyslipidemia: Epidemiology
The dyslipidemia epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted dyslipidemia epidemiology segmented as the prevalent cases of dyslipidemia, diagnosed cases of dyslipidemia, gender-specific diagnosed cases of dyslipidemia, prevalence of genetic dyslipidemia by types and lipid-specific diagnosed cases. The report includes the prevalent scenario of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria from 2019 to 2032.
Country-wise Dyslipidemia Epidemiology
The epidemiology segment also provides the dyslipidemia epidemiology data and findings across Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
Total prevalent cases of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) was approximately 83 million cases in 2021.
According to the estimates, Turkey had the most prevalent dyslipidemia in 2021. On the other hand, Portugal had the lowest prevalent population with approximately 3.4 million cases in 2021.
Scope of the Report
Dyslipidemia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
Dyslipidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria).
The report provides insight into the historical and forecasted patient pool of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
The report helps recognize the growth opportunities in the emerging markets concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of dyslipidemia.
The report provides the segmentation of the dyslipidemia epidemiology by prevalent cases of dyslipidemia in the emerging markets.
The report provides the segmentation of the dyslipidemia epidemiology by diagnosed prevalent cases of dyslipidemia in the emerging markets.
The report provides the segmentation of the dyslipidemia epidemiology by Gender-specific cases of dyslipidemia in emerging markets.
The report provides the segmentation of the dyslipidemia epidemiology by Prevalence of genetic dyslipidemia by types in emerging markets.
The report provides the segmentation of the dyslipidemia epidemiology by Lipid-specific cases of dyslipidemia in emerging markets.
Report Highlights
11-year Forecast of Dyslipidemia epidemiology
Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria Coverage
Prevalent cases of dyslipidemia
Diagnosed cases of dyslipidemia
Gender-specific diagnosed cases of dyslipidemia
Prevalence of genetic dyslipidemia by types
Lipid-specific diagnosed cases of dyslipidemia
KOL Views
We interview KOLs and obtain SMEs opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.
Key Questions Answered
What are the major factors that will drive the change in patient population with dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) during the forecast period (20192032)?
What are the key findings pertaining to dyslipidemia epidemiology across emerging markets, and which country will have the highest number of patients during the forecast period (20192032)?
What would be the total number of patients with dyslipidemia across the emerging markets during the forecast period (20192032)?
At what CAGR is the patient population expected to grow in the emerging markets forecast period (20192032)?
What are the disease risk, burdens, and unmet needs of dyslipidemia?
What are the currently available treatments for dyslipidemia?
Reasons to buy
Dyslipidemia Epidemiology report will allow the user to:
Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market
Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans
Understand the magnitude of the dyslipidemia population by its prevalent cases.
Understand the magnitude of the dyslipidemia population by its gender-specific cases.
Understand the magnitude of the dyslipidemia population by its prevalence of genetic dyslipidemia by types.
Understand the magnitude of the dyslipidemia population by its lipid-specific diagnosed cases of dyslipidemia.
The dyslipidemia epidemiology report and model were written and developed by Masters and PhD level epidemiologists
The dyslipidemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
Portugal
Switzerland
Greece
Turkey
Poland
Netherlands
Belgium
Austria
Study Period: 20192032
1. Key Insights
2. Report Introduction
3. Dyslipidemia Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Dyslipidemia in 2019
3.2. Patient Share (%) Distribution of Dyslipidemia in 2032
4. Executive Summary of Dyslipidemia
5. Disease Background and Overview
5.1. Introduction
5.2. Classification
5.3. Signs and Symptoms
5.4. Etiology
5.5. Pathogenesis
5.6. Diagnosis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Prevalent Cases of Dyslipidemia in the Emerging Markets
6.3. Assumptions and Rationale
6.4. Portugal
6.4.1. Prevalent Cases of Dyslipidemia in Portugal
6.4.2. Diagnosed Cases of Dyslipidemia in Portugal
6.4.3. Gender-specific Diagnosed Cases of Dyslipidemia in Portugal
6.4.4. Prevalence of Genetic Dyslipidemia by Types in Portugal
6.4.5. Lipid-specific Diagnosed Cases in Portugal
6.5. Switzerland
6.5.1. Prevalent Cases of Dyslipidemia in Switzerland
6.5.2. Diagnosed Cases of Dyslipidemia in Switzerland
6.5.3. Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland
6.5.4. Prevalence of Genetic Dyslipidemia by Types in Switzerland
6.5.5. Lipid-specific Diagnosed Cases in Switzerland
6.6. Greece
6.6.1. Prevalent Cases of Dyslipidemia in Greece
6.6.2. Diagnosed Cases of Dyslipidemia in Greece
6.6.3. Gender-specific Diagnosed Cases of Dyslipidemia in Greece
6.6.4. Prevalence of Genetic Dyslipidemia by Types in Greece
6.6.5. Lipid-specific Diagnosed Cases in Greece
6.7. Turkey
6.7.1. Prevalent Cases of Dyslipidemia in Turkey
6.7.2. Diagnosed Cases of Dyslipidemia in Turkey
6.7.3. Gender-specific Diagnosed Cases of Dyslipidemia in Turkey
6.7.4. Prevalence of Genetic Dyslipidemia by Types in Turkey
6.7.5. Lipid-specific Diagnosed Cases in Turkey
6.8. Poland
6.8.1. Prevalent Cases of Dyslipidemia in Poland
6.8.2. Diagnosed Cases of Dyslipidemia in Poland
6.8.3. Gender-specific Diagnosed Cases of Dyslipidemia in Poland
6.8.4. Prevalence of Genetic Dyslipidemia by Types in Poland
6.8.5. Lipid-specific Diagnosed Cases in Poland
6.9. Netherlands
6.9.1. Prevalent Cases of Dyslipidemia in the Netherlands
6.9.2. Diagnosed Cases of Dyslipidemia in the Netherlands
6.9.3. Gender-specific Diagnosed Cases of Dyslipidemia in the Netherlands
6.9.4. Prevalence of Genetic Dyslipidemia by Types in the Netherlands
6.9.5. Lipid-specific Diagnosed Cases in the Netherlands
6.10. Belgium
6.10.1. Prevalent Cases of Dyslipidemia in Belgium
6.10.2. Diagnosed Cases of Dyslipidemia in Belgium
6.10.3. Gender-specific Diagnosed Cases of Dyslipidemia in Belgium
6.10.4. Prevalence of Genetic Dyslipidemia by Types in Belgium
6.10.5. Lipid-specific Diagnosed Cases in Belgium
6.11. Austria
6.11.1. Prevalent Cases of Dyslipidemia in Austria
6.11.2. Diagnosed Cases of Dyslipidemia in Austria
6.11.3. Gender-specific Diagnosed Cases of Dyslipidemia in Austria
6.11.4. Prevalence of Genetic Dyslipidemia by Types in Austria
6.11.5. Lipid-specific Diagnosed Cases in Austria
7. Patient Journey
8. KOL Views
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Table 1: Summary of Dyslipidemia: Epidemiology (20192032)
Table 2: Genetic classification of Dyslipidemia
Table 3: The Criteria for Diagnosis of Dyslipidemia
Table 4: Total Diagnosed Prevalent Population of Dyslipidemia in 000s (20192032)
Table 5: Prevalent Cases of Dyslipidemia in Portugal in 000s (20192032)
Table 6: Diagnosed Cases of Dyslipidemia in Portugal in 000s (20192032)
Table 7: Gender-specificspecific Diagnosed Cases of Dyslipidemia in Portugal (20192032)
Table 8: Prevalence of Genetic Dyslipidemia by Types in Portugal (20192032)
Table 9: Lipid-specific Diagnosed Cases in Portugal (20192032)
Table 10: Prevalent Cases of Dyslipidemia in Switzerland in 000s (20192032)
Table 11: Diagnosed Cases of Dyslipidemia in Switzerland in 000s (20192032)
Table 12: Gender-specific Diagnosed Cases of Dyslipidemia in 000s in Switzerland (20192032)
Table 13: Prevalence of Genetic Dyslipidemia by Types in Switzerland (20192032)
Table 14: Lipid-specific Diagnosed Cases in Switzerland (20192032)
Table 15: Prevalent Cases of Dyslipidemia in Greece in 000s (20192032)
Table 16: Diagnosed Cases of Dyslipidemia in Greece in 000s (20192032)
Table 17: Gender-specific Diagnosed Cases of Dyslipidemia in Greece (20192032)
Table 18: Prevalence of Genetic Dyslipidemia by Types in Greece (20192032)
Table 19: Lipid-specific Diagnosed Cases in Greece (20192032)
Table 20: Prevalent Cases of Dyslipidemia in 000s Turkey (20192032)
Table 21: Diagnosed Cases of Dyslipidemia in Turkey in 000s (20192032)
Table 22: Gender-specific Diagnosed Cases of Dyslipidemia in Turkey in 000s (20192032)
Table 23: Prevalence of Genetic Dyslipidemia by Types in Turkey (20192032)
Table 24: Lipid-specific Diagnosed Cases in Turkey in 000s (20192032)
Table 25: Prevalent Cases of Dyslipidemia in 000s Poland (20192032)
Table 26: Diagnosed Cases of Dyslipidemia in Poland in 000s (20192032)
Table 27: Gender-specific Diagnosed Cases of Dyslipidemia in 000s Poland (20192032)
Table 28: Prevalence of Genetic Dyslipidemia by Types in Poland (20192032)
Table 29: Lipid-specific Diagnosed Cases in 000s Poland (20192032)
Table 30: Prevalent Cases of Dyslipidemia in the Netherlands in 000s (20192032)
Table 31: Diagnosed Cases of Dyslipidemia in the Netherlands in 000s (20192032)
Table 32: Gender-specific Diagnosed Cases of Dyslipidemia in Netherlands 000s (20192032)
Table 33: Prevalence of Genetic Dyslipidemia by Types in Netherlands 000s (20192032)
Table 34: Lipid-specific Diagnosed Cases in the Netherlands in 000s (20192032)
Table 35: Prevalent Cases of Dyslipidemia in Belgium in 000s (20192032)
Table 36: Diagnosed Cases of Dyslipidemia in Belgium 000s (20192032)
Table 37: Gender-specific Diagnosed Cases of Dyslipidemia in Belgium in 000s (20192032)
Table 38: Prevalence of Genetic Dyslipidemia by Types in Belgium (20192032)
Table 39: Lipid-specific Diagnosed Cases in Belgium in 000s(20192032)
Table 40: Prevalent Cases of Dyslipidemia in Austria in 000s (20192032)
Table 41: Diagnosed Cases of Dyslipidemia in Austria in 000s (20192032)
Table 42: Gender-specific Diagnosed Cases of Dyslipidemia in Austria in 000s (20192032)
Table 43: Prevalence of Genetic Dyslipidemia by Types in Austria (20192032)
Table 44: Lipid-specific Diagnosed Cases in Austria in 000s (20192032)
Figure 1: Dyslipidemic states
Figure 2: Classification of Dyslipidemia
Figure 3: Eyelid Xanthelasmas
Figure 4: Tendinous xanthomas at the Achilles
Figure 5: Xanthomas over back
Figure 6: Causes of Dyslipidemia
Figure 7: Total Prevalent Cases of Dyslipidemia in the Emerging Markets in 000s (20192032)
Figure 8: Prevalent Cases of Dyslipidemia in 000s in Portugal (20192032)
Figure 9: Diagnosed Cases of Dyslipidemia in 000s in Portugal (20192032)
Figure 10: Gender-specific Diagnosed Cases of Dyslipidemia in Portugal in 000s (20192032)
Figure 11: Prevalence of Genetic Dyslipidemia by Types in Portugal in 000s (20192032)
Figure 12: Lipid-specific Diagnosed Cases in Portugal in 000s (20192032)
Figure 13: Prevalent Cases of Dyslipidemia in Switzerland in 000s (20192032)
Figure 14: Diagnosed Cases of Dyslipidemia in Switzerland in 000s (20192032)
Figure 15: Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland in 000s (20192032)
Figure 16: Prevalence of Genetic Dyslipidemia by Types in Switzerland in 000s (20192032)
Figure 17: Lipid-specific Diagnosed Cases in Switzerland in 000s (20192032)
Figure 18: Prevalent Cases of Dyslipidemia in Greece in 000s (20192032)
Figure 19: Diagnosed Cases of Dyslipidemia in Greece in 000s (20192032)
Figure 20: Gender-specific Diagnosed Cases of Dyslipidemia in Greece in 000s (20192032)
Figure 21: Prevalence of Genetic Dyslipidemia by Types in Greece in 000s (20192032)
Figure 22: Lipid-specific Diagnosed Cases in Greece in 000s (20192032)
Figure 23: Prevalent Cases of Dyslipidemia in Turkey in 000s (20192032)
Figure 24: Diagnosed Cases of Dyslipidemia in Turkey in 000s (20192032)
Figure 25: Gender-specific Diagnosed Cases of Dyslipidemia in Turkey in 000s (20192032)
Figure 26: Prevalence of Genetic Dyslipidemia by Types in Turkey in 000s (20192032)
Figure 27: Lipid-specific Diagnosed Cases in Turkey in 000s (20192032)
Figure 28: Prevalent Cases of Dyslipidemia in Poland in 000s (20192032)
Figure 29: Diagnosed Cases of Dyslipidemia in Poland in 000s (20192032)
Figure 30: Gender-specific Diagnosed Cases of Dyslipidemia in Poland in 000s (20192032)
Figure 31: Prevalence of Genetic Dyslipidemia by Types in Poland in 000s (20192032)
Figure 32: Lipid-specific Diagnosed Cases in Poland in 000s (20192032)
Figure 33: Prevalent Cases of Dyslipidemia in the Netherlands in 000s (20192032)
Figure 34: Diagnosed Cases of Dyslipidemia in the Netherlands in 000s (20192032)
Figure 35: Gender-specific Diagnosed Cases of Dyslipidemia in the Netherlands in 000s (20192032)
Figure 36: Prevalence of Genetic Dyslipidemia by Types in the Netherlands in 000s (20192032)
Figure 37: Lipid-specific Diagnosed Cases in the Netherlands in 000s (20192032)
Figure 38: Prevalent Cases of Dyslipidemia in Belgium in 000s (20192032)
Figure 39: Diagnosed Cases of Dyslipidemia in Belgium in 000s (20192032)
Figure 40: Gender-specific Diagnosed Cases of Dyslipidemia in Belgium in 000s (20192032)
Figure 41: Prevalence of Genetic Dyslipidemia by Types in Belgium in 000s (20192032)
Figure 42: Lipid-specific Diagnosed Cases in Belgium in 000s (20192032)
Figure 43: Cases of Dyslipidemia in Austria in 000s (20192032)
Figure 44: Diagnosed Cases of Dyslipidemia in Austria in 000s (20192032)
Figure 45: Gender-specific Diagnosed Cases of Dyslipidemia in Austria in 000s (20192032)
Figure 46: Prevalence of Genetic Dyslipidemia by Types in Austria in 000s (20192032)
Figure 47: Lipid-specific Diagnosed Cases in Austria in 000s (20192032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security